Genzyme sharpens diagnostic focus:
This article was originally published in Clinica
Genzyme has continued refocusing its diagnostics business towards higher-value products by selling its bioreagent and ELISA immunochemistry lines to Alexon-Trend, a subsidiary of Sybron International. These product lines, which are supplied to diagnostics companies and OEM manufacturers, generated revenues of $3.1 million in 1998. Last year, Cambridge, Massachusetts-based Genzyme sold its research products business to Techne for $65 million. Financial terms of the latest transaction were not revealed. Separately, Milwaukee, Wisconsin-based Sybron's microbiology subsidiary, Remel, has acquired the assets of Micro Test, which manufactures transport media for infectious organisms.